Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


QUOTED. March 6, 2018. Mary Jensen.

Executive Summary

Check out what US FDA Neurological Devices Panel Chair Mary Jensen had to say about the biggest point of debate at a recent panel meeting that focused on clinical trial requirements for intracranial aneurysm devices.


"I think the biggest bone of contention here was, what do you do with small unruptured aneurysms? Do you include them in the trial?" – Mary Jensen, panel chair, FDA’s Neurological Devices Panel

Click here for a free trial of Medtech Insight


Related Content

Brain Trust Advises US FDA On Aneurysm Device Trials





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts